GLP-1 side effects and 'mom hacks': what the science says

What did @missusmom actually say?

After four years on Wegovy (semaglutide) and 83 pounds lost, @missusmom switched to compounded tirzepatide to chase an additional 20 pounds. She says the switch eliminated her constipation, sulfur burps, uncomfortable fullness, and what she describes as suppressed energy. She later also tried brand-name Zepbound with insurance coverage. Her bottom line: "tirzepatide is a better product" for her personally.

To be clear, she is not making a universal medical claim. She is comparing her own subjective experience across two different drug classes. That context matters a lot for how we evaluate what she's saying. She is also, notably, helping others access compounded medications, which means she has a stake in how compelling this comparison sounds. That is worth keeping in mind.

Does the science back this up?

The head-to-head data here is limited but genuinely suggestive. Tirzepatide acts on both GIP and GLP-1 receptors, while semaglutide targets only GLP-1. That dual mechanism appears to produce meaningfully different outcomes in some patients.

The SURMOUNT-5 trial (Jastreboff et al., 2025, NEJM) directly compared tirzepatide and semaglutide in adults with obesity and found tirzepatide produced about 20% greater weight loss over 72 weeks. On side effects, the picture is more nuanced. GI events were common in both arms. Constipation rates differed, and nausea profiles were not identical, but neither drug is clearly "gentler" for everyone. The SCALE and STEP trials showed semaglutide's GI burden is real and dose-dependent. Tirzepatide's GI profile from SURMOUNT trials also showed significant nausea and diarrhea, though constipation rates trended lower in some analyses.

Her energy observation is anecdotal but not implausible. There is no robust trial data specifically comparing fatigue across these two agents, so that claim sits in the "plausible but unproven" zone.

What did they get wrong (or right)?

She got the broad strokes right. Tirzepatide and semaglutide are pharmacologically distinct, and individual tolerance varies significantly. It is entirely reasonable that someone could feel better on one versus the other.

Where she goes wrong, or at least gets sloppy, is implying that compounded tirzepatide delivered the same therapeutic experience as brand-name Zepbound. She essentially uses the two interchangeably in her narrative. That is a problem. Compounded drugs are not FDA-approved, are not required to demonstrate bioequivalence, and their potency and sterility are only as good as the compounding pharmacy producing them. The FDA has flagged serious concerns about compounded GLP-1 products, including dosing errors and contamination reports.

Her sulfur burp complaint with semaglutide is real and documented. A 2023 survey-based analysis (Butner et al., Obesity Medicine) confirmed sulfur belching as a commonly underreported semaglutide side effect. Tirzepatide appears to produce this less frequently, though formal comparative data is thin.

What should you actually know?

If you are on semaglutide and feeling stuck or managing side effects that are genuinely affecting your quality of life, asking your provider about tirzepatide is a reasonable conversation. SURMOUNT-5 gives that conversation clinical grounding. But do not take a TikTok testimonial as a clinical roadmap.

A few things to be clear-eyed about. First, compounded tirzepatide is not the same product as Zepbound, legally or pharmacologically. She conflates them throughout, and that conflation can mislead people into thinking they are getting an equivalent drug at a lower cost with no trade-offs. Second, four years of weight maintenance on Wegovy is genuinely impressive and suggests the drug was working. Switching to chase an extra 20 pounds is a personal choice, not a clinical necessity. Third, the side effect profile she describes, especially constipation and energy suppression, is real and worth discussing with a provider. But individual responses vary enormously, and her experience is not predictive of yours.

• Tirzepatide and semaglutide are different drug classes with different mechanisms.
• SURMOUNT-5 showed tirzepatide outperformed semaglutide on weight loss, but both carry GI side effect burdens.
• Compounded GLP-1 medications are not FDA-approved and should not be treated as equivalent to brand-name drugs.

Bottom line: credible experience, some important gaps

She is speaking from real experience and mostly stays in her lane. The problem is that her lane intersects with helping others access compounded medications, and the line between personal testimony and implicit recommendation blurs quickly on a platform like TikTok. Her side effect comparison is plausible. Her conflation of compounded and brand-name tirzepatide is not something anyone should casually repeat.